Sentence examples for molecular subtype that from inspiring English sources

Therefore, the identification of proteins that are abundantly and predominantly expressed in ovarian cancer presents a valuable undertaking and may provide early clues to the presence of ovarian cancer, and/or indications of a molecular subtype that could help to guide treatment.

In particular, this applies to BC cell lines with a basal molecular subtype that have most probably undergone epithelial-to-mesenchymal transition in culture.

A tumor is assigned to the molecular subtype that has the highest correlation between the subtype's centroid and the study tumor's corresponding gene expression pattern [ 2- 4, 6].

The basal-like subtype of breast cancer is a molecular subtype that was originally discovered through gene expression profiling studies [ 1– 3, 75].

Basal-like breast carcinoma (BBC) is a molecular subtype that constitutes 15 20% of breast cancers, shares histological similarities and basal cell markers with ACC, lacks expression of ER (oestrogen receptor), PR (progesterone receptor), and HER2 (human epidermal growth factor receptor 2), and, similar to ACC, metastasises predominantly to the lung and brain.

Seventy-three percent of TNBC displayed basal-like molecular subtype that correlated with high histological grade and younger age.

Importantly, breast cancer cannot be considered a single disease as it is characterized by distinct pathological and molecular subtypes that are treated with different therapies and have diverse clinical outcomes.

Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease.

In the last decade, comprehensive whole genome expression profiling by microarray technology has extensively defined breast cancer into distinct molecular subtypes that differ in terms of patient outcome and response to systemic treatment.

Among the adenocarcinomas, no significant segregation was observed on this analysis that would suggest subclassification into distinct molecular subtypes that might be associated with differences in tumor or cellular staging criteria.

Similarly, additional targets are required for other molecular subtypes that fail to respond to existing therapies.